143 related articles for article (PubMed ID: 22795202)
1. Vaccine prospect of Kaposi sarcoma-associated herpesvirus.
Wu TT; Qian J; Ang J; Sun R
Curr Opin Virol; 2012 Aug; 2(4):482-8. PubMed ID: 22795202
[TBL] [Abstract][Full Text] [Related]
2. Is murine gammaherpesvirus-68 (MHV-68) a suitable immunotoxicological model for examining immunomodulatory drug-associated viral recrudescence?
Aligo J; Walker M; Bugelski P; Weinstock D
J Immunotoxicol; 2015; 12(1):1-15. PubMed ID: 24512328
[TBL] [Abstract][Full Text] [Related]
3. Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 infection in reactive lymphoid tissues: a model for KSHV/HHV-8-related lymphomas?
Lazzi S; Bellan C; Amato T; Palummo N; Cardone C; D'Amuri A; De Luca F; Beyanga M; Facchetti F; Tosi P; Leoncini L
Hum Pathol; 2006 Jan; 37(1):23-31. PubMed ID: 16360412
[TBL] [Abstract][Full Text] [Related]
4. BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV.
Barasa AK; Ye P; Phelps M; Arivudainambi GT; Tison T; Ogembo JG
Oncotarget; 2017 May; 8(21):34481-34497. PubMed ID: 28404899
[TBL] [Abstract][Full Text] [Related]
5. Kaposi sarcoma herpesvirus pathogenesis.
Mariggiò G; Koch S; Schulz TF
Philos Trans R Soc Lond B Biol Sci; 2017 Oct; 372(1732):. PubMed ID: 28893942
[TBL] [Abstract][Full Text] [Related]
6. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
[TBL] [Abstract][Full Text] [Related]
7. Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma.
Kimball LE; Casper C; Koelle DM; Morrow R; Corey L; Vieira J
J Infect Dis; 2004 Jun; 189(11):2016-22. PubMed ID: 15143468
[TBL] [Abstract][Full Text] [Related]
8. Molecular and immunohistochemical detection of Kaposi sarcoma herpesvirus/human herpesvirus-8.
Chadburn A; Wilson J; Wang YL
Methods Mol Biol; 2013; 999():245-56. PubMed ID: 23666704
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen.
Simpson GR; Schulz TF; Whitby D; Cook PM; Boshoff C; Rainbow L; Howard MR; Gao SJ; Bohenzky RA; Simmonds P; Lee C; de Ruiter A; Hatzakis A; Tedder RS; Weller IV; Weiss RA; Moore PS
Lancet; 1996 Oct; 348(9035):1133-8. PubMed ID: 8888167
[TBL] [Abstract][Full Text] [Related]
10. Mono/oligoclonal pattern of Kaposi Sarcoma-associated herpesvirus (KSHV/HHV-8) episomes in primary effusion lymphoma cells.
Boulanger E; Duprez R; Delabesse E; Gabarre J; Macintyre E; Gessain A
Int J Cancer; 2005 Jul; 115(4):511-8. PubMed ID: 15700304
[TBL] [Abstract][Full Text] [Related]
11. Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma.
Lambert M; Gannagé M; Karras A; Abel M; Legendre C; Kerob D; Agbalika F; Girard PM; Lebbe C; Caillat-Zucman S
Blood; 2006 Dec; 108(12):3871-80. PubMed ID: 16926293
[TBL] [Abstract][Full Text] [Related]
12. Antibodies against Kaposi sarcoma-associated herpes virus (KSHV) complement control protein (KCP) in infected individuals.
Okroj M; Spiller OB; Korodi Z; Tedeschi R; Dillner J; Blom AM
Vaccine; 2007 Nov; 25(48):8102-9. PubMed ID: 17964697
[TBL] [Abstract][Full Text] [Related]
13. Kaposi's sarcoma-associated herpesvirus (KSHV)/human herpesvirus 8 (HHV-8) as a tumour virus.
Cathomas G
Herpes; 2003 Dec; 10(3):72-7. PubMed ID: 14759339
[TBL] [Abstract][Full Text] [Related]
14. Persistence of Kaposi sarcoma-associated herpesvirus (KSHV)-infected cells in KSHV/HIV-1-coinfected subjects without KSHV-associated diseases.
Campbell TB; Staskus KA; Folkvord J; White IE; Neid J; Zhang XQ; Connick E
J Infect Dis; 2005 Feb; 191(3):367-71. PubMed ID: 15633095
[TBL] [Abstract][Full Text] [Related]
15. The sero-epidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in adults with cancer in Uganda.
Newton R; Ziegler J; Bourboulia D; Casabonne D; Beral V; Mbidde E; Carpenter L; Reeves G; Parkin DM; Wabinga H; Mbulaiteye S; Jaffe H; Weiss R; Boshoff C;
Int J Cancer; 2003 Jan; 103(2):226-32. PubMed ID: 12455037
[TBL] [Abstract][Full Text] [Related]
16. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis.
Grundhoff A; Ganem D
J Clin Invest; 2004 Jan; 113(1):124-36. PubMed ID: 14702116
[TBL] [Abstract][Full Text] [Related]
17. Immune evasion by Kaposi's sarcoma-associated herpesvirus.
Coscoy L
Nat Rev Immunol; 2007 May; 7(5):391-401. PubMed ID: 17457345
[TBL] [Abstract][Full Text] [Related]
18. New viruses shake old paradigms.
Wang CY; Sugden B
J Clin Invest; 2004 Jan; 113(1):21-3. PubMed ID: 14702103
[TBL] [Abstract][Full Text] [Related]
19. Kaposi's Sarcoma (KS)-associated herpesvirus and its role in KS.
Chang Y; Moore PS
Infect Agents Dis; 1996 Oct; 5(4):215-22. PubMed ID: 8884366
[TBL] [Abstract][Full Text] [Related]
20. The role of Kaposi sarcoma-associated herpesvirus in the pathogenesis of Kaposi sarcoma.
Gramolelli S; Schulz TF
J Pathol; 2015 Jan; 235(2):368-80. PubMed ID: 25212381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
